Evolving Treatment for Patients With BD
Patients with Behçet disease (BD)—or Behçet syndrome (BS), as documented in the study—require risk assessment, analyzation of disease activity, and appropriate adjustment of treatment, according to a recent study.
Researchers analyzed the clinical data, demographics, and other reported characteristics of patients with BD in China during a retrospective analysis of 174 patients. Using univariate and multivariate logistic regression, they analyzed demographic data and laboratory indexes to identify risk factors of disease activity.
The authors found varying symptoms and disease activity manifestations, depending on treatment.
“The most common clinical manifestations of BS patients enrolled were mouth ulceration (48.85%), followed by erythema nodosum (20.69%), and eye involvement (13.75%), while the least common was headache (0%). Most active BS patients (96.55%) used 2 or ≥ 3 immunosuppressants to control disease, while most inactive patients (75%) used 0 or 1 immunosuppressant,” the authors reported.
“The associated risk factors of disease activity consisted of disease duration, neutrophil-to-lymphocyte ratio, white blood cells, red blood cells, hemoglobin, platelets, fibrin degradation products, IgG, IgM, complement 3, complement 4, C-reactive protein, erythrocyte sedimentation rate, albumin, albumin-to-globulin ratio, and high-density lipoprotein,” they concluded.
--Angelique Platas
Reference:
Hou, Cc., Guan, Jl. Risk factors of disease activity in patients with Behçet’s syndrome. Clin Rheumatol 2021; 40(4): 1465–1471.
